Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2014-11-04 Director's Dealing
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
Director's Dealing 2014
Director's Dealing
2014-11-04 English
Director's Dealing 2014
Director's Dealing
2014-11-04 English
10-Q
Interim / Quarterly Report Q3 2014
2014-10-30 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and includes a press release announcing sales and earnings for the third quarter and nine months ended September 28, 2014. It also references unaudited supplementary sales data and condensed consolidated statement of earnings. This indicates it is an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document length is short (2406 characters), but it contains actual financial highlights and is not merely an announcement of a report being published elsewhere. Therefore, the correct classification is Earnings Release (ER).
2014-10-14 English
8-K
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events. The text describes an acquisition agreement by Johnson & Johnson to acquire Alios BioPharma, including details about the transaction and regulatory conditions. There is no detailed financial data or comprehensive report content, but rather an announcement of a merger/acquisition event. The document also references a press release attached as an exhibit. Given the nature of the content—announcement of a merger agreement—and the form type (8-K), the appropriate classification is Merger & Acquisition (MA). The document length is short and it is not a full report but an announcement of a transaction event, fitting the MA category rather than a full annual or interim report or a regulatory filing fallback.
2014-10-02 English
Director's Dealing 2014
Director's Dealing
2014-09-11 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.